Agenda

The event design includes engaging debates, panels and roundtable discussions to foster interaction between participants and stimulate them to search for solutions to the real challenges and opportunities in the industry that will enable change.

download precision medicine programme1.jpg

PRELIMINARY Agenda

(Subject to change)

MONDAY 13 NOVEMBER 2017

16:00-18:00
THE DEBATE: 

CONTROVERSIES IN PRECISION MEDICINE

Moderators: Dan Peer, Martin Lohse, Christian Elze

We will introduce why and how we are at point of controversies today. The opening debate will explore whether a genetic-driven approach just needs more time to produce results or whether we need to first invest more in a regulatory filtering of genetic variations.

Read more about the speakers here>

WELCOME FROM SUMMIT CHAIRPERSON

Dan Peer
Director, Tel Aviv University Cancer Biology Research Center, Tel Aviv, Israel

OPENING ADDRESS

Martin Lohse
Chair of the Board of Directors and Scientific Director of the Max Delbrück Center for Molecular Medicine in the Helmholtz Association
Member of the Board of Directors of the Berlin Institute of Health (BIH), Berlin, Germany

Debaters:

Richard Fitzgerald
Director, Clinical Research Unit, RLUH, Liverpool, UK

Denis Noble
Emeritus Professor of Cardiovascular Physiology, Oxford, UK

Panel Discussion with Audience Questions 

18:00-19:00

BUSINESS PERSPECTIVE

How to bring precision medicine to fields outside of oncology, mendelian rare diseases and infection diseases. We will review what has worked or not worked to date and therefore factors we need to be considering in moving forward. We will hone-in on how to approach building more viable businesses in precision medicine.

Read more about the speakers here>

Christian Elze
Senior Partner Catenion, London, UK

Robert Wasserman
Chief Medical Officer at Northern Biologics, Toronto, Canada 

19:00NETWORKING RECEPTION


TUESDAY 14 NOVEMBER 2017

8:30-10:15

PRECISION MEDICINE - THE PHARMACEUTICAL STANDPOINT

Pre-Disease Intervention: Bringing Precision Medicine from the Back End to the Front End of Diseases. We will focus on how industry perceives the current challenges in precision medicine and their outlook based on specific case studies.

Read more about the speakers here>

Speakers:

Thomas Bock
Chairman and Chief Executive Officer HeritX, Santa Monica, USA

Matthias Ocker
Head of Biomarker Strategy, Bayer AG, Berlin, Germany 

Ludwig Heesen
Project Manager Clinical Studies, BioNTech, Mainz, Germany

Round Table Discussions

10:15-10:45Coffee Break, Networking & Exhibition 
10:45-12:55

PRECISION MEDICINE IN
THE CLINIC - CLINICAL STANDPOINT

Case Studies & Panel Discussion on the clinical benefit

We will seek to understand when a precision medicine approach will be beneficial and when it is unlikely to be so. If we can increase our understanding, then we can better focus on increasing the efficiency of precision medicine based drugs.

Read more about the speakers here>

Chair: Michael Heuser
Heisenberg Chair for Molecular Therapies in Hematology, Hannover Medical School, Hannover, Germany

Speakers:

Ido Wolf
Head, Oncology Division, Tel Aviv Medical Center, Tel Aviv, Israel

Michael Heuser
Heisenberg Chair for Molecular Therapies in Hematology, Hannover Medical School, Hannover, Germany

Pia Raanani
Head of The Hematology Devision in Rabin Medical Center, Tel Aviv, Israel

Ulrich Keilholz
Acting Director, Charité Comprehensive Cancer Center, Berlin, Germany

Round Table Discussions

13:00-14:00     Lunch, Networking & Exhibition
14:00-15:45

PATIENT STRATIFICATION VIA GENOMICS/EPI-GENOMICS IN CANCER

Through the power of genomics and epi-genomics, we are starting to see some success in patient stratification for treating cancer. However, we currently lack the necessary tools to fully process and analyse the data in many cases, such as when multiple patients' phenotype data does not correspond to shared genome level mutations. How can we improve our data and what next steps do we need in clinical informatics?

Read more about the speakers here>

Speakers:

Erez Levanon
Associate Professor at The Mina and Everard Faculty of Life Sciences, Bar-Ilan University Ramat Gan, Israel

Xiangdong Wang
Director Shanghai Institute Clinical Bioinformatics, Fudan University Zhongshan Hospital, Shanghai, China

Manfred Dietel 
Full Professor and Director of the Institute Charité, Berlin, Germany

Round Table Discussions

15:45-16:15Coffee break, Networking & Exhibition 
16:15-18:00

DEVELOPING NEW DELIVERY VEHICLES FOR PRECISION MEDICINE

Much of the potential of precision medicine rests on drug delivery strategies. What is achievable with current drug carriers and where do we need to focus in our current pipeline? How can precision medicine benefit from nanomedicine? And if the future of precision medicine lies in altering nucleic acid, then where do we need to focus our research to make it a reality?

Read more about the speakers here>

Speakers:

Heinrich Haas
Vice President RNA Formulation & Drug Delivery at BioNTech RNA Pharmaceuticals, Mainz, Germany

James Taylor
Co-founder, CEO at Precision NanoSystems, Inc., Vancouver, Canada

Twan Lammers
Head of department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Aachen, Germany

Round Table Discussions

18:00-19:15

THE FUTURE OF PRECISION MEDICINE FROM A REGULATORY STANDPOINT 

Regulatory agencies will present their view on the emerging field of precision medicine and what they are seeing as the needed criteria to ensure a fair and efficient approval process.

Read more about the speakers here>

Speakers:

Khaled Bouri
Science Advisor Office of Regulatory Science and Innovation, Food and Drug Administration, Silver Spring, USA

Christopher Rowe 
Innovation Lead, Precision Medicine, Innovate UK, Swindon, UK




WEDNESDAY 15 NOVEMBER 2017

08:30-10:15

DISEASE SIGNATURE AND SMALL VS. BIG DATA IN PRECISION MEDICINE

This session will review the challenges of operating without an aligned definition of disease signature. We will consider the amount of data we are processing, both small and big data, as well as whether we should be taking advantage of clinical trials to collect as much real-time physical and environmental data.

Read more about the speakers> 

Speakers:

Mira Marcus-Kalish
Director, International Research Affairs, Tel-Aviv University Ramat Aviv, Tel Aviv, Israel

Yelena Yesha 
Professor, Department of Computer Science and Electrical Engineering, University of Maryland, Baltimore County, USA

Ancha Baranova
Associate Professor, School of Systems Biology, George Mason University, Fairfax, USA

Round Table Discussions

10:15-10:45Coffee Break, Networking & Exhibition
10:45-12:30

HEALTH INFORMATICS

How do we analyse complex diseases? Are computer-based solutions such as AI and machine learning the best solution direction? What is their potential and limitations? 

Read more about the speakers here> 

Speakers:

Harsha Rajasimha
Global Head, Life Sciences R&D, NTT DATA Inc., Washington, USA 

Sahar Gelfman
Institute for Genomic Medicine, Columbia University Medical Center, New York, USA

Edit Buzas
Professor and Chair at Semmelweis University, Department of Genetics, Cell- and  Immunobiology, Budapest, Hungary

Round Table Discussions

12:30-13:30Lunch, Networking & Exhibition 
13:30-14:30

THE POWER OF PRECISION MEDICINE IN RARE DISEASE 

Panel discussion: The Role of Foundations in Precision Medicine

The field of rare diseases is expanding to the point of more than 10,000 sub-diseases. There is a lack of single drugs suitable for enough of these sub-diseases, which has made the drug discovery process less financially attractive and riskier for pharma. The challenge for precision medicine is to develop a global drug solution where there is a common denominator. Where are we at and how can the market move forward?

Read more about the speakers> 

Panellists:

Amylynne Volker 
Founder Nicholas Volker One In A Billion Foundation, USA

Peter Kapitein
President and Patient Advocate Inspire2Live, Amsterdam, Netherlands

Janet Allen
Director of Strategic Innovation at Cystic Fibrosis Trust, London, UK 

14:30-16:15

NEW THERAPEUTIC MODALITIES FOR RARE DISEASE 

Is there potential for a new protein or messenger RNA that will fit all mutations and generate a global solution for a disease? Case studies on this and other novel approaches for treating rare diseases.

Read more about the speakers> 

Speakers:

Eran Blaugrund
VP R&D, ART BioScience Ltd, Rehvot, Israel 

Stuart Hughes
Director and Head of Pharmacology at Vertex Pharmaceuticals, London, UK

Round Table Discussions

16:15-16:45Coffee break, Networking & Exhibition
16:45 - 17:15

CLOSING - SUMMARY & DISCUSSION 

Panel Discussion on the next steps for precision medicine. Summary of where are the challenges and what are the potential solutions.